Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:49 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Bevacizumab vs Dacarbazine in Metastatic Melanoma
NCT01705392 · Haukeland University Hospital · PHASE2 · terminated · last registry update 2017-02-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of financing of the study drug. Not sufficient financial support.” | – | Registry record, Haukeland University Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against VEGFA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2017-10-25Phase 3 first posted: Jaeb Center for Health Research, intravitreous aflibercept + Bevacizumab + Deferred Aflibercept Group (NCT03321513)
- 2017-09-13Results posted on the registry: University of Oklahoma, Intravitreal Aflibercept Injection (NCT01805297)
- 2017-07-21Phase 3 first posted: Chengdu Kanghong Biotech Co., Ltd., Conbercept Ophthalmic Injection + sham injection (NCT03223714)
- 2017-06-01Phase 3 first posted: Centre Hospitalier Universitaire de Nice, Aflibercept Injection + False injection (NCT03172299)
- 2017-04-11Phase 3 first posted: Chengdu Kanghong Biotech Co., Ltd., Conbercept ophthalmic injection (NCT03108352)
- 2016-04-27Results posted on the registry: National Eye Institute (NEI), Ranibizumab + Bevacizumab (NCT01610557)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision